| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on. |
businesswire.com |
2025-05-02 11:00:00 |
Czytaj oryginał (ang.) |
| KalVista: Poised For Rare Disease Transformation |
KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial position with $253.2 million in cash, bolstered by $160 million in recent financing, ensures readiness for commercialization. Strategic partnerships, including a licensing deal with Kaken Pharmaceutical in Japan, and successful pediatric trial progress, de-risk and expand market potential. |
seekingalpha.com |
2025-04-12 04:42:55 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement o. |
businesswire.com |
2025-04-08 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 87,000 shares of KalVista common stock on April 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on. |
businesswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals,. |
businesswire.com |
2025-03-31 11:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE). “We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial siz. |
businesswire.com |
2025-03-25 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company's investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here. In addition to presentations by KalVista's management team,. |
businesswire.com |
2025-03-10 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. “The growing body of data from the KONFIDENT-S study consistently demo. |
businesswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. The following poster presentations will take place on Friday, February 28, 2025, from 2:45–3:45 pm PT in the Convention Center, Ground Level,. |
businesswire.com |
2025-02-21 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting taking place in Waimea, HI from February 9-13, 2025. Raffi Tachdjian, MD, MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School. |
businesswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 61,000 shares of KalVista common stock on January 2, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock. |
businesswire.com |
2025-01-08 08:30:00 |
Czytaj oryginał (ang.) |
| KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 |
NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. |
seekingalpha.com |
2024-12-18 15:46:24 |
Czytaj oryginał (ang.) |
| KalVista Appoints Jeb Ledell as Chief Operating Officer |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. “I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within. |
businesswire.com |
2024-12-16 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today released financial results for the second fiscal quarter ended October 31, 2024. The Company also provided an operational update, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of a New Drug Application (NDA) for sebetralstat, a novel, investigational treatment for hereditary angioedema (HAE). “KalVista is successfully executing on the key milestones we announced a. |
businesswire.com |
2024-12-05 08:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have. |
businesswire.com |
2024-12-04 08:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. “I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors,” said Ben Palleiko, Chief E. |
businesswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals to Present at Upcoming Investor Conferences |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will be live webcast on the Company's website at www.kalvista.com. After the presentations,. |
businesswire.com |
2024-11-12 08:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts, commissions and other offering expenses payable by KalVista. Concurrently with the Offering, Kal. |
businesswire.com |
2024-11-04 09:05:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised of a $100 million upfront payment, a one-time $22 million optional payment upon U.S. product approval, and up to $57 million in a sales-based milestone payment. The proceeds of this transaction will be used to fund the commercialization of sebe. |
businesswire.com |
2024-11-04 09:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of new sebetralstat data at the American College of Allergy Asthma and Immunology (ACAAI) taking place in Boston, MA from October 24 - 28, 2024. Tim Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health, and KONFIDENT investigator, presented data on the Correlation of Time to T. |
businesswire.com |
2024-10-28 08:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Boston, MA from October 24-28. Presentations include: Patient-Reported Anxiety Impacts Utilization of Injectable On-demand Treatment of Hereditary Angioedema Attacks: Cristine Radojicic, Autum. |
businesswire.com |
2024-10-18 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark, October 4 - 5, 2024. These data were generated in the KONFIDENT phase 3 clinical trial, for which the Company disclosed top line results in February 2024. |
businesswire.com |
2024-10-04 16:29:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of KalVista common stock on October 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an. |
businesswire.com |
2024-10-02 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in the United Kingdom, Switzerland, Australia, and Singapore for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. The four MAAs have been submitted via the. |
businesswire.com |
2024-09-30 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark October 4-5, 2024. The following nine abstracts have been accepted for poster presentation on Friday, October 4 between 6:00-7:00pm CET: Impact of Oral Sebetralstat on Anxiety Associated with Hereditary Angioedema Attacks in the Phase 3 KONFIDENT Trial: Marcus Maur. |
businesswire.com |
2024-09-26 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Appoints Brian Piekos as Chief Financial Officer |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. “Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for. |
businesswire.com |
2024-09-10 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented additional analyses of the efficacy and safety of sebetralstat from phase 2 and phase 3 double-blind, placebo-controlled crossover clinical trials as well as interim data from KONFIDENT-S, a phase 3 open-label extension trial, and real-world patient data at the Bradykinin Symposium 2024 taking place in Berlin, Germany, on September 5-6. Sebetralstat is a novel. |
businesswire.com |
2024-09-06 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts at the 2024 Bradykinin Symposium taking place in Berlin, Germany September 5-6, 2024. The following presentations will take place on Friday, September 6 in the Kaiserin Friedrich-Haus Lecture Hall: Oral Presentations Delayed On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported by Italian patients: Mauro Canci. |
businesswire.com |
2024-08-29 10:30:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted eleven newly-hired employees inducement options to purchase an aggregate of 90,000 shares of KalVista common stock on August 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have. |
businesswire.com |
2024-08-02 10:30:00 |
Czytaj oryginał (ang.) |
| Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch |
KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and Japan launches. KalVista raised $150.1 million in February 2024, securing a cash runway approximately 2.2 years after the raise. |
seekingalpha.com |
2024-06-24 06:53:53 |
Czytaj oryginał (ang.) |
| KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older. “This NDA submission represents a pivotal moment not only for our company, but for. |
businesswire.com |
2024-06-18 10:30:00 |
Czytaj oryginał (ang.) |